Ana Martinez – författare

Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.

For more than five centuries, the Plaza Mayor (or Zócalo) in Mexico City has been the site of performances for a public spectatorship. During the period of colonial rule, performances designed to ensure loyalty to the Spanish monarchy were staged there, but over time, these displays gave way to staged demonstrations of resistance. Today, the Zócalo is a site for both official government-sponsored celebrations and performances that challenge the state. Performance in the Zócalo examines the ways that this city square has achieved symbolic significance over the centuries, and how national, ethnic, and racial identity has been performed there.A saying in Mexico City is “quien domina el centro, domina el país” (whoever dominates the center, dominates the country) as the Zócalo continues to act as the performative embodiment of Mexican society. This book highlights how particular performances build upon each other by recycling past architectures and performative practices for new purposes. Ana Martínez discusses the singular role of collective memory in creating meaning through space and landmarks, providing a new perspective and further insight into the problem of Mexico’s relationship with its own past. Rather than merely describe the commemorations, she traces the relationship between space and the invention of a Mexican imaginary. She also explores how indigenous communities, Mexico’s alienated subalterns, performed as exploited objects, exotic characters, and subjects with agency. The book’s dual purposes are to examine the Zócalo as Mexico’s central site of performance and to unmask, without homogenizing, the official discourse regarding Mexico’s natives. This book will be of interest for students and scholars in theater studies, Mexican Studies, Cultural Geography, Latinx and Latin American Studies.

Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials. Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

Affecting over 1.5 million people across the world, Parkinson's disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson´s disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson´s disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinson´s disease. This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinson´s drug market in the next few years as potential disease modifying drugs. Providing up to date and comprehensive coverage, this book is essential reading for researchers working in academia and industry in any aspect of medicinal chemistry or drug discovery.

"Låt oss vårda och bejaka de underhållande aspekterna i våra kulturkrockar. Låt oss välkomna situationer där människor av olika arter och med olika livssyn genom kulturkrocken har förmåtts att ge sig själva och varandra i en försonande skrattspegel. Jag vill påstå att historierna i denna bok har en skrattspegelkvalitet som påminner om att varje kulturkrock bär ett givande möte i sitt sköte." Ana Martinez, ur förkrocken